Will the FDA extend Merck’s ENFLONSIA to a second RSV season at its March 22 review?

Question

This market will resolve YES if the FDA issues a marketing approval for Merck’s ENFLONSIA (clesrovimab-cfor) covering children under two years at increased risk of severe RSV disease entering their second RSV season in the review cycle with the announced target date of 2027-03-22. The legally effective approval and authorised indication control, not the date the medicine reaches pharmacies. The existing first-season indication is insufficient: the authorised label must expressly include eligible

Problyx · Accepted Answer

Yes — the community forecast puts this at 83%.

Problyx · Answer

No — the community forecast puts this at 17%.